Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria

A. M. Giménez‐Arnau; E. Toubi; A. M. Marsland; M. Maurer

doi:10.1111/jdv.13697

journal article Jun 10, 2016

Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria

A. M. Giménez‐Arnau E. Toubi A. M. Marsland M. Maurer

Journal of the European Academy of Dermatology and Venereology Vol. 30 No. S5 pp. 25-32 · Wiley

View at Publisher Save 10.1111/jdv.13697

Abstract

AbstractThis supplement reports proceedings of the second international Global Urticaria Forum, which was held in Berlin, Germany in November 2015. Omalizumab is approved for the treatment of chronic spontaneous urticaria (CSU) in adult and adolescent (12 years and above) patients with inadequate response to/who remain symptomatic despite H1‐antihistamine treatment, and has demonstrated good efficacy and safety in the clinical trial setting. Real‐life clinical experience with omalizumab can be explored to address important practical questions relating to its use in CSU patients. Some experts have proposed that a consensus algorithm, covering various aspects to consider when using omalizumab in real‐life clinical practice for the management of CSU, could answer many of these questions.

Topics

No keywords indexed for this article. Browse by subject →

References

39

[1]

European Medicines Evaluation Agency (EMEA).Omalizumab (Xolair) summary of product characteristics (SmPC). [WWW document]2014. URLhttp://www.ema.europa.eu(last accessed: 22 March 2016).

[2]

Genentech Inc.Xolair: FDA Prescribing Information. [WWW document]2010. Updated July 2010. URLhttp://www.gene.com/download/pdf/xolair_prescribing.pdf(last accessed: 22 March 2016).

[3]

10.1111/all.12313

[4]

10.1111/j.1398-9995.2010.02496.x

[5]

10.1186/s13223-015-0088-7

[6]

10.1016/j.jaci.2013.05.013

[7]

10.1056/nejmoa1215372

[8]

10.1038/jid.2014.306

[9]

10.1016/j.jaci.2015.12.1342

[10]

10.1016/j.jaip.2015.04.015

[11]

10.1111/all.12870

[12]

10.1016/j.jaci.2011.04.038

[13]

10.1016/j.jaci.2011.06.010

[14]

10.1016/j.jdermsci.2013.08.011

[15]

Rottem M "Omalizumab therapy for chronic spontaneous urticaria: the Israeli experience" Isr Med Assoc J (2014)

[16]

10.1016/j.anai.2013.12.005

[17]

10.1517/14712598.2013.822484

[18]

10.1001/jamadermatol.2013.8705

[19]

10.1111/all.12209

[20]

10.1016/j.jaci.2013.12.1076

[21]

10.1111/ijd.12727

[22]

10.1016/j.jaci.2015.08.023

[23]

10.1016/j.anai.2009.11.017

[24]

10.5114/pdia.2014.44023

[25]

10.1016/j.aller.2013.11.007

[26]

10.1016/j.jaci.2013.10.015

[27]

10.1016/j.anai.2015.05.010

[28]

10.1016/j.jaci.2014.12.1350

[29]

Novartis (2014)

[30]

10.1111/j.1365-2222.2009.03214.x

[31]

10.1016/j.jaci.2007.09.022

[32]

10.1016/j.jaci.2007.09.032

[33]

10.1016/j.jaci.2014.02.036

[34]

10.5415/apallergy.2012.2.2.149

[35]

10.1111/cea.12465

[36]

Termeer C "Chronic spontaneous urticaria ‐ a management pathway for patients with chronic spontaneous urticaria" J Dtsch Dermatol Ges (2015) 10.1111/ddg.12633

[37]

National Institute of Health and Care Excellence (NICE).NICE technology appraisal guidance 339: Omalizumab for previously treated chronic spontaneous urticaria. [WWW document]2015. Issued June 2015. URLhttps://www.nice.org.uk/guidance/ta339(last accessed: 22 March 2016).

[38]

10.1186/2045-7022-2-19

[39]

10.1016/j.jaip.2015.11.025

Metrics

49

Citations

39

References

Details

Published: Jun 10, 2016
Vol/Issue: 30(S5)
Pages: 25-32
License: View

Authors

A

A. M. Giménez‐Arnau

Department of Dermatology Hospital del Mar Universitat Autònoma de Barcelona Barcelona Spain

E

E. Toubi

Division of Allergy and Clinical Immunology Bnai‐Zion Medical Center Haifa Israel

A

A. M. Marsland

Salford Royal NHS Foundation Trust Manchester Academic Health Science Center University of Manchester Manchester UK

M

M. Maurer

Department of Dermatology and Allergy Allergie‐Centrum‐Charité Charité – Universitätsmedizin Berlin Berlin Germany

Funding

Novartis Pharma AG

Cite This Article

A. M. Giménez‐Arnau, E. Toubi, A. M. Marsland, et al. (2016). Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria. Journal of the European Academy of Dermatology and Venereology, 30(S5), 25-32. https://doi.org/10.1111/jdv.13697

Clinical management of urticaria using omalizumab: the first licensed biological therapy available for chronic spontaneous urticaria

You May Also Like